ERBB2 and breast carcinoma: T-DM1 is used in the adjuvant or neoadjuvant aspects of breast cancer: The KATHERINE trial (NCT01772472) demonstrated that adjuvant therapy with T-DM1 significantly reduces the risk of recurrence or death in patients with early-stage HER2-positive breast cancer.